Our submissions to government offer an important opportunity to influence policy and keep dementia research on the agenda.

Commons Health Committee Brexit and health and social care inquiry (October 2016)

This inquiry sought views on health and social care issues that should be considered during Brexit negotiations. Our response urged policymakers to seek a continued relationship with the European Medicines Agency, in order to prevent any delays in future dementia treatments reaching UK patients. We also called for continued support for dementia research, including support for cross-border collaborations, sharing of resources for research and access to EU funding programmes.

Scottish Parliament European and External Relations Committee Inquiry into Scotland’s relationship with the EU (September 2016)

As part of this inquiry, organisations were asked to submit evidence on the implications for Scotland of the UK’s decision to leave the EU. In our response, we called for scientific representation during Brexit talks, and outlined key priorities for protecting dementia research in any new relationship with the EU.

House of Lords Select Committee on Charities Call for Evidence on charity sector sustainability (September 2016)

This committee was set up in 2016 to consider the sustainability of the charity sector and charity governance. Our submission to the inquiry outlined the unique value charities have to play in society, as well as the ways charities can underpin their work with good governance practices.

Alzheimer’s Research UK and Alzheimer’s Society combined submission to the House of Lords Science and Technology Select Committee EU membership and UK science follow-up (August 2016)

Ahead of the EU Referendum, this House of Lords inquiry set out to examine the relationship between the UK’s membership of the European Union and its world-leading capability in science. Following a call for further evidence after the vote to leave the EU, our joint response with the Alzheimer’s Society stressed the need for continued access to EU funding schemes, continued mobility for talented research staff, and support for collaboration to allow the UK to remain a positive force in the EU research environment.

House of Commons Science and Technology Select Committee Inquiry into leaving the EU (August 2016)

Following the UK’s vote to leave the EU, this House of Commons inquiry invited organisations to submit evidence on the potential implications and opportunities for science and research. In our submission, we underlined the benefits EU membership have brought for UK science, and called for these to be protected during Brexit negotiations.

Health Select Committee enquiry into Impact of membership of the EU on health policy in the UK (May 2016)

To help inform the EU Referendum debate, this Health Select Committee inquiry set out to gather evidence on the impact of the EU on health policy in the UK. Our response highlighted the importance of EU funding sources for medical research, its role as a catalyst for collaboration among dementia researchers, and the benefits of EU-wide information and resource sharing.

Science and Technology Committee inquiry into Science communication (April 2016)

This inquiry examined how government, scientists, the media and others enable public awareness of and engagement in science, as well as barriers to be overcome. Science communication is vitally important for helping the public to understand the progress being made in dementia research, and for helping people understand how advances reported in the media may impact their own lives. Our response to the inquiry focused on the opportunity to dispel misunderstanding through clarity in media reporting, and the role of charities in helping foster public engagement.

Input to draft National Institute for Health and Care Excellence guidelines on Dementia: supporting people with dementia and their carers in health and social care (March 2016)

This consultation from NICE sought views to help develop guidance on preventing, diagnosing, assessing and managing dementia, with particular recommendations for the management of Alzheimer's disease. We highlighted the importance of an accurate and timely diagnosis, and the need to address variation in the way the condition is managed in different parts of the country, with clear guidelines for GPs about the impact of existing treatments.

Response to Health Select Committee inquiry on Impact of the Comprehensive Spending Review on health and social care (January 2016)

Following the publication of the 2015 Comprehensive Spending Review, which set out government spending for the following four years, this inquiry was established to examine the impact of these spending decisions on health and social care. In our written evidence, we raised concerns about the potential impact of cuts to local authority public health budgets, warning that a loss of funding could set back the government’s commitment to reducing the risk of dementia across the population.

Our policy work

We're working with governments worldwide, funders, industry, and people impacted by dementia to support life-changing research.


Join us by signing up to become a campaigner.

Policy reports

Our reports provide the evidence we need to campaign for dementia research.